Halozyme Therapeutics, Inc.Financials
|
|
Halozyme Therapeutics, Inc. (HALO) financial statements from SEC filings: income statement, balance sheet and cash flow, by year and quarter.
Historical Financials
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,396,611,000 | 1,015,324,000 | 829,253,000 | 660,116,000 | 443,310,000 | 267,594,000 | 195,992,000 | 151,862,000 | 316,613,000 | 146,691,000 | |
| Cost of Revenue | 228,774,000 | 159,417,000 | 192,361,000 | 139,304,000 | 81,413,000 | 43,367,000 | 45,546,000 | 10,136,000 | 31,152,000 | 33,206,000 | |
| Gross Profit | 1,167,837,000 | 855,907,000 | 636,892,000 | 520,812,000 | 361,897,000 | 3,741,000 | 3,749,000 | 3,890,000 | 5,178,000 | 5,178,000 |
Sign up to view full financial statements
Create a free CapEdge account to access balance sheet, cash flow, and complete historical data.
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin (%) | |||||||||||
| R&D Expense | |||||||||||
| SG&A Expense | |||||||||||
| Total Operating Expenses | |||||||||||
| Operating Income or Loss | |||||||||||
| Operating Margin (%) | |||||||||||
| EBITDA | |||||||||||
| Interest Expense | |||||||||||
| Non-Operating Income/Expense | |||||||||||
| Income Before Tax | |||||||||||
| Income Tax Expense | |||||||||||
| Income from Continuing Ops. | |||||||||||
| Net Income | |||||||||||
| Net Profit Margin (%) | |||||||||||
| Basic EPS | |||||||||||
| Diluted EPS | |||||||||||
| Basic Average Shares | |||||||||||
| Diluted Average Shares |
All numbers in thousands. Financial statements are in beta and sourced from EDGAR XBRL filings. Read the caveats.